Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer

ConclusionDespite limitations, this subgroup analysis suggests that ramucirumab monotherapy improves efficacy outcomes with a tolerable safety profile in EA patients with previously treated advanced gastric cancer.

Source: Asia-Pacific Journal of Clinical Oncology - December 1, 2017 Category: Cancer & Oncology Authors: Hyun Cheol Chung, Victor C. Kok, Rebecca Cheng, Yanzhi Hsu, Mauro Orlando, Charles Fuchs, Jae Yong Cho Tags: ORIGINAL ARTICLE Source Type: research